MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies
Not intended for human or animal consumption
Similarly, any existing lesion that changes size, shape, or color should be evaluated promptly
Optional Add-On Toradol (Ketorolac): For pain, inflammation, or body aches during illness
If youre losing weight quickly and arent strength training, your body has fewer reasons to hold onto muscle
Compounded Medication Notice: SkinnyRx's primary medication offerings are compounded prescription products prepared by licensed 503A pharmacies based on individual prescriptions